Tags: Drug.
NGD-4715 is a drug developed by Neurogen which acts as a selective non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal studies it has anxiolytic antidepressant and anorectic effects and it has successfully passed Phase I clinical trials in humans.Neurogen was acquired by Ligand Pharmaceuticals in August 2009 and NGD-4715 was not listed among the key assets in the Business Wire article.
